Why the study?
Gene therapy targeting cardiac diseases is still lagging behind despite advances in AAV vector development.
Highlights the need for further research and development of adeno-associated viral (AAV) vectors with improved cardiac tropism for the treatment of heart diseases.
New liver-detargeted AAV capsids improve muscle/heart transduction in mice and NHPs; leaves open human safety, dosing, and durability.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Miguel‐dos‐Santos et al. (2023) conducted an editorial in Cardiac diseases. Adeno-associated viral vectors (AAVs) gene therapies was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: